Search

Author/Creator Erickson, Rebecca

2. DNL104, a Centrally Penetrant RIPK1 Inhibitor, Inhibits RIP1 Kinase Phosphorylation in a Randomized Phase I Ascending Dose Study in Healthy Volunteers. Issue 2 (25th September 2019)

Authors:
Grievink, Hendrika W.; Heuberger, Jules A.A.C.; Huang, Fen; Chaudhary, Rinkal; Birkhoff, Willem A.J.; Tonn, George R.; Mosesova, Sofia; Erickson, Rebecca; Moerland, Matthijs; Haddick, Patrick C.G.; Scearce‐Levie, Kimberly; Ho, Carole; Groeneveld, Geert Jan
Journal:
Clinical pharmacology & therapeutics
Issue:
Volume 107:Issue 2(2020)
Page Start:
406
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Safety, pharmacokinetics and target engagement of novel RIPK1 inhibitor SAR443060 (DNL747) for neurodegenerative disorders: Randomized, placebo‐controlled, double‐blind phase I/Ib studies in healthy subjects and patients. Issue 8 (1st June 2022)

Authors:
Vissers, Maurits F. J. M.; Heuberger, Jules A. A. C.; Groeneveld, Geert Jan; Oude Nijhuis, Jerome; De Deyn, Peter Paul; Hadi, Salah; Harris, Jeffrey; Tsai, Richard M.; Cruz‐Herranz, Andres; Huang, Fen; Tong, Vincent; Erickson, Rebecca; Zhu, Yuda; Scearce‐Levie, Kimberly; Hsiao‐Nakamoto, Jennifer;...
Journal:
Clinical and translational science
Issue:
Volume 15:Issue 8(2022)
Page Start:
2010
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗